BACKGROUND: Helicobacter hepaticus infection might be associated with liver and biliary tract diseases. To investigate its pathogenic role, the properties of anti-H. hepaticus serum antibody in patients with liver and diseases were elucidated. METHODS: Serum samples were collected from 166 patients-69 with liver diseases, 38 with upper gastrointestinal diseases, 17 with lower gastrointestinal diseases, 26 with biliary tract diseases, and 16 with pancreas diseases; 30 control sera were obtained from 30 healthy blood donors. Serum samples were analyzed by enzyme-linked immunosorbent assay (ELISA) and western blot using the new monoclonal antibody HR II-51. RESULTS: Anti-H. hepaticus serum antibody concentrations in patients with liver disease (n = 69) were significantly increased compared with those in other disease groups (p = 0.014 to <0.001). Particularly, liver cirrhosis (n = 19) showed a significantly higher antibody level compared with other liver diseases (n = 50, p = 0.005) and healthy donors (n = 30, p = 0.0005), as well as a higher seroprevalence (68.4%) compared with other liver diseases (p = 0.05) and healthy donors (p = 0.004). Furthermore, the ELISA value in liver cirrhosis (n = 19) was significantly higher than that in patients with hepatitis B virus (HBV)-and/or hepatitis C virus (HCV)-infected chronic hepatitis (n = 15) (0.389 ± 0.084 vs. 0.350 ± 0.084, p = 0.029). However, there was no relationship between the total immunoglobulin concentration and the anti-H. hepaticus antibody level in each liver disease (Spearman's rank correlation coefficient [rs] < 0.225). CONCLUSIONS: H. hepaticus infection might play a role in the development of liver diseases; in particular, it might increase the risk of the development of HBV- and/or HCV-infected liver diseases.
BACKGROUND:Helicobacter hepaticus infection might be associated with liver and biliary tract diseases. To investigate its pathogenic role, the properties of anti-H. hepaticus serum antibody in patients with liver and diseases were elucidated. METHODS: Serum samples were collected from 166 patients-69 with liver diseases, 38 with upper gastrointestinal diseases, 17 with lower gastrointestinal diseases, 26 with biliary tract diseases, and 16 with pancreas diseases; 30 control sera were obtained from 30 healthy blood donors. Serum samples were analyzed by enzyme-linked immunosorbent assay (ELISA) and western blot using the new monoclonal antibody HR II-51. RESULTS: Anti-H. hepaticus serum antibody concentrations in patients with liver disease (n = 69) were significantly increased compared with those in other disease groups (p = 0.014 to <0.001). Particularly, liver cirrhosis (n = 19) showed a significantly higher antibody level compared with other liver diseases (n = 50, p = 0.005) and healthy donors (n = 30, p = 0.0005), as well as a higher seroprevalence (68.4%) compared with other liver diseases (p = 0.05) and healthy donors (p = 0.004). Furthermore, the ELISA value in liver cirrhosis (n = 19) was significantly higher than that in patients with hepatitis B virus (HBV)-and/or hepatitis C virus (HCV)-infected chronic hepatitis (n = 15) (0.389 ± 0.084 vs. 0.350 ± 0.084, p = 0.029). However, there was no relationship between the total immunoglobulin concentration and the anti-H. hepaticus antibody level in each liver disease (Spearman's rank correlation coefficient [rs] < 0.225). CONCLUSIONS: H. hepaticus infection might play a role in the development of liver diseases; in particular, it might increase the risk of the development of HBV- and/or HCV-infected liver diseases.
Authors: M Rocha; P Avenaud; A Ménard; B Le Bail; C Balabaud; P Bioulac-Sage; D M de Magalhães Queiroz; F Mégraud Journal: Gut Date: 2005-03 Impact factor: 23.059
Authors: J G Fox; F E Dewhirst; Z Shen; Y Feng; N S Taylor; B J Paster; R L Ericson; C N Lau; P Correa; J C Araya; I Roa Journal: Gastroenterology Date: 1998-04 Impact factor: 22.682
Authors: J G Fox; F E Dewhirst; J G Tully; B J Paster; L Yan; N S Taylor; M J Collins; P L Gorelick; J M Ward Journal: J Clin Microbiol Date: 1994-05 Impact factor: 5.948
Authors: J M Ward; J G Fox; M R Anver; D C Haines; C V George; M J Collins; P L Gorelick; K Nagashima; M A Gonda; R V Gilden Journal: J Natl Cancer Inst Date: 1994-08-17 Impact factor: 13.506
Authors: J G Fox; Y Feng; E J Theve; A R Raczynski; J L A Fiala; A L Doernte; M Williams; J L McFaline; J M Essigmann; D B Schauer; S R Tannenbaum; P C Dedon; S A Weinman; S M Lemon; R C Fry; A B Rogers Journal: Gut Date: 2010-01 Impact factor: 23.059
Authors: Matthew Silbergleit; Adrian A Vasquez; Carol J Miller; Jun Sun; Ikuko Kato Journal: Prog Mol Biol Transl Sci Date: 2020-04-09 Impact factor: 3.622